Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support (U54 Clinical Trial Not Allowed)

Closed Posted

Opportunity number
RFA-DA-27-015
Agency
Applications due
Award size
Not on record

Opportunity facts

Assistance listings
Funding instrument
Cooperative Agreement
Category
  • Health
Eligible applicants
  • Special District Governments
  • Higher Education Inst. (Public)
  • Tribal Governments (Federally Recognized)
  • County Governments
  • 501(c)(3) Nonprofits
  • Tribal Organizations (Not Federally Recognized)
  • Higher Education Inst. (Private)
  • For Profit Organizations
  • Independent School Districts
  • Other
  • City/Township Governments
  • Public or Indian Housing Auth.
  • Small Businesses
  • Non-501(c)(3) Nonprofits
  • State Governments
Points of contact

Opportunity details come from Grants.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The National Institute on Drug Abuse (NIDA) seeks applicants to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support, with applications due September 30, 2026.

Eligible applicants include higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, state and local governments, tribal governments (federally recognized and non-federally recognized), special districts, independent school districts, public or Indian housing authorities, and small businesses. Foreign organizations are eligible; however, applications involving foreign subawards are not permitted.

NIDA will commit $3 million to fund one cooperative agreement award with a maximum project period of 5 years and an earliest start date of September 30, 2026. The Center must establish four integrated cores: an Administrative Core for overall management and coordination; an Outreach and Networking Core to recruit academic researchers and establish mentorship networks with drug developers, regulatory experts, and intellectual property specialists; a Drug Development Training and Education Core to deliver a customized curriculum in SUD pharmacotherapeutic development, including a 2–3 day in-person session; and a Preclinical Study Support Core to solicit, evaluate, and manage subawards for early-stage feasibility studies conducted over less than 6 months.

Applications must follow Multi-Project (M) Instructions with specific page limits: Overall (12 pages), Administrative Core (6 pages), Outreach and Networking Core (6 pages), Drug Development Training and Education Core (6 pages), and Preclinical Study Support Core (6 pages). All applications must be submitted electronically through ASSIST or institutional system-to-system solutions. Scientific merit review is anticipated in March 2027, advisory council review in May 2027, and funding decisions in July 2027. The program is assigned CFDA 93.279 (Drug Use and Addiction Research Programs).

Synopsis

The purpose of this notice of funding opportunity (NOFO) is to establish a Center that trains researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Files

File Type Posted
PKG00292872.pdf PDF
RFA-DA-27-015-Full-Announcement.html HTML file

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar grant opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login